← Back to Search

Unknown

KBL697 for Psoriasis

Phase 2
Waitlist Available
Led By Deirdre Murrell
Research Sponsored by KoBioLabs
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have chronic plaque type psoriasis of moderate severity
Male or female, aged 18 to 75 years (inclusive)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to weeks 4, 8 and 12
Awards & highlights

Study Summary

This trial will test the effectiveness and safety of KBL697, a potential new treatment for plaque psoriasis.

Who is the study for?
This trial is for men and women aged 18-75 with chronic moderate plaque type psoriasis, diagnosed at least 6 months ago. Participants must commit to using reliable contraception. It's not for those with drug-induced psoriasis, other skin diseases that could affect results, or who failed two or more systemic treatments.Check my eligibility
What is being tested?
The study tests the effectiveness and safety of a new potential treatment called KBL697 specifically developed for Moderate Plaque Type Psoriasis. The goal is to see how well it works compared to existing treatments.See study design
What are the potential side effects?
While specific side effects of KBL697 are not listed here, common side effects in psoriasis treatments may include skin irritation, headaches, fatigue, nausea and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have long-term moderate plaque psoriasis.
Select...
I am between 18 and 75 years old.
Select...
I have been diagnosed with plaque psoriasis for at least 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to weeks 4, 8 and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to weeks 4, 8 and 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Physician's Global Assessment (PGA)
Psoriasis Area and Severity Index (PASI)
Psoriasis Area and Severity Index (PASI) -50
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low dose groupExperimental Treatment1 Intervention
39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
Group II: High dose groupExperimental Treatment1 Intervention
39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
KBL697
2019
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

KoBioLabsLead Sponsor
3 Previous Clinical Trials
54 Total Patients Enrolled
Deirdre MurrellPrincipal InvestigatorPremier Specialist
Paul YamauchiPrincipal InvestigatorClinical Science Institute

Media Library

KBL697 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04911751 — Phase 2
Psoriasis Research Study Groups: Low dose group, High dose group
Psoriasis Clinical Trial 2023: KBL697 Highlights & Side Effects. Trial Name: NCT04911751 — Phase 2
KBL697 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04911751 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available openings to join this research trial?

"According to the information hosted on clinicaltrials.gov, recruitment for this trial is ongoing. It was initially made public on November 8th 2021 and its most recent update came out of September 6th 2022."

Answered by AI

How many individuals are engaging in this research endeavor?

"Affirmative. According to clinicaltrials.gov, recruitment is still ongoing for this experiment which was published on November 8th 2021 and has been recently amended on September 6th 2022. The research necessitates the participation of 80 patients from 6 medical centres."

Answered by AI

How many venues provide access to this trial?

"Currently, 6 medical sites are enrolling patients in this study. These locations include Santa Ana, Birmingham and Doral among a few other places. To reduce the need for travel when taking part in the trial, it is advisable to select your closest centre."

Answered by AI

Does this medical experiment accept applicants who are over 55 years old?

"This clinical trial requires a specific age bracket, ranging from 18 to 75 years old. There are 31 studies that cater specifically to those under the legal age of majority, and 142 for patients over 65."

Answered by AI

Does KBL697 possess the certification of the Food and Drug Administration?

"Due to the Phase 2 nature of this trial, our evaluation yielded a safety score of two for KBL697. This indicates that there is existing evidence supporting its security but none indicating efficacy."

Answered by AI

What criteria must a participant meet in order to be eligible for this research?

"This medical experiment is looking for 80 participants, aged between 18 to 75 years of age and currently being affected by psoriatic plaque. To be eligible, they must also fulfil the following requirements: exhibiting chronic plaque type psoriasis with a moderate severity rating and identifying as either male or female."

Answered by AI
~24 spots leftby Mar 2025